The Friedman Brain Institute offers comprehensive inpatient and outpatient care for patients with traumatic brain injuries (TBI) and spinal cord injuries (SCI).
We offer treatment programs at these locations:
Treatment starts immediately upon arrival. Our team of acute care physicians, including surgeons, therapists, and nurses, works to stabilize the initial injury and to minimize secondary damage to the peripheral nerves. Once the acute trauma is stabilized, a multidisciplinary team initiates inpatient rehabilitation focused on your needs and those of your care providers. No two injuries – whether to the brain, the spinal cord or both – are completely alike. Our individualized approach aims to maximize independence and smooth your transition back to home. We manage cognitive effects, spasticity, mobility, hand skills, bowel and bladder function, sexual health, and reintegration into the community.
Our 360-degree care continues to address your physical, cognitive, and social needs after you have transitioned from the inpatient setting. Multiple innovative basic and clinical research programs at both Mount Sinai and the James J. Peters Veterans Affairs Medical Center ensure you can benefit from the newest medical breakthroughs. Our overall goal is to enhance neurological recovery, maximize independence, and improve quality of life for patients who have suffered TBI or SCI and their caregivers.
Our investigators have many active projects in the laboratory and the clinic. We have received prominent national funding awards to study all aspects of TBI and SCI mechanisms, their societal impact, and treatment. Our areas of study include basic research into the cellular mechanisms of neural injury and repair.
Individuals who have suffered a brain or spinal cord injury, either recently or long ago, may be eligible to participate in one of the many trials offered through The Friedman Brain Institute at either the Mount Sinai Health System or at the James J. Peters Veterans Affairs Medical Center. This is an opportunity for eligible patients to freely access therapies that may not yet be offered in general practice or covered by insurance.
Some of our ongoing studies include: